Ascletis hits near 6-month high on obesity drug application to U.S. FDA

Ascletis Pharma

11/02/2026 03:10

** Shares of Ascletis Pharma Inc 1672.HK jump 8.8% to HK$18.64, their highest level since August 18, and on course for fourth straight session of gains

** Company says it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development

** Ascletis expects to submit an Investigational New Drug Application to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026

** YTD, stock up 59.8%, Hang Seng Biotech Index .HSBIO up 13.2%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))